Cancer News and Research

Latest Cancer News and Research

Substance tackles skin cancer with two-pronged attack

By playing it safe and using a two-pronged attack, a novel designer molecule fights malignant melanoma. It was created and tested by an international team of researchers led by the University of Bonn.

2 Nov 2008

Bacteria can directly cause human blood and plasma to clot

Bacteria can directly cause human blood and plasma to clot - a process that was previously thought to have been lost during the course of vertebrate evolution, according to new research at the University of Chicago, National Institute of Allergy and Infectious Diseases, and Institut Pasteur in Paris. Their findings will be published online Nov. 2 in Nature Chemical Biology.

2 Nov 2008

Side effects predict succes of breast cancer treatment

Hot flushes, night sweats and painful joints can be a blessing in disguise for breast cancer patients - according to a new report published online in the Lancet Oncology.

2 Nov 2008

Vigorous exercise protects against breast cancer

Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.

31 Oct 2008

Research points to new treatment options for infantile hemangioma

A team of researchers led by Harvard School of Dental Medicine (HSDM) Dean for Research Bjorn Olsen has discovered a mechanism for the rapid growth seen in infantile hemangioma, the most common childhood tumor.

31 Oct 2008

Frequent urination protects against bladder cancer

A new study has analysed the effect of urinary frequency on the risk of bladder cancer. The conditions of this research which is published in the latest number of the International Journal of Cancer, show a direct association between the number of times people get up at night to urinate and protection against bladder cancer.

30 Oct 2008

Gleevec holds potential as first drug to successfully treat neurofibromatosis

Researchers at the Indiana University School of Medicine report that the anti-cancer drug Gleevec holds out promise to become the first effective treatment for neurofibromatosis, a genetic disease that has resisted treatments until now.

30 Oct 2008

Discovery of mechanism and possible drug treatment for growth of nerve tumors in neurofibromatosis

Researchers studying neurofibromatosis type 1 - a rare disease in which tumors grow within nerves - have found that the tumors are triggered by crosstalk between cells in the nerves and cells in the blood.

30 Oct 2008

By imaging live cells, researchers show how hepatitis C replicates

The hepatitis C virus is a prolific replicator, able to produce up to a trillion particles per day in an infected person by hijacking liver cells in which to build up its viral replication machinery.

30 Oct 2008

Cancer requires support from immune system to develop, researchers report

Tumors that grow around nerves in a rare genetic disease need cooperation from cells from the immune system in order to grow, reports a team of scientists, including researchers from UT Southwestern Medical Center.

30 Oct 2008

Starpharma's VivaGelR patent approved in Japan

Starpharma Holdings Limited today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.

29 Oct 2008

Researchers discover new way to attack some forms of leukemia

Each year, some 29,000 adults and 2,000 children are diagnosed with leukemia, a form of cancer that is caused by the abnormal production of white blood cells in the bone marrow. Current treatments rely primarily on killing the cancer cells, which also destroys normal cells. But what if a way could be found to reprogram cancerous cells back into normal cells? A team of Syracuse University researchers believes it may have found a way to do just that.

28 Oct 2008

New signpost to clinical trial expertise

A new comprehensive online resource listing national expertise in the design and conduct of clinical trials is launched today. The UKCRC Registered Clinical Trials Units website provides, for the first time, centralised information on Clinical Trials Units (CTUs) in the UK - including the Bristol Randomised Trials Collaboration (BRTC) at the University of Bristol.

28 Oct 2008

Phenomix starts phase 1a trial of hepatitis C protease inhibitor

Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company's internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

28 Oct 2008

Selenium and vitamin E supplements do not prevent prostate cancer

Initial, independent review of study data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT), funded by the National Cancer Institute (NCI) and other institutes that comprise the National Institutes of Health shows that selenium and vitamin E supplements, taken either alone or together, did not prevent prostate cancer.

28 Oct 2008

Systems biology and glycomics used to study human inflammatory diseases

An innovative systems biology approach to understanding the carbohydrate structures in cells is leading to new ways to understand how inflammatory illnesses and cardiovascular disease develop in humans. The work was described in two recent publications by University at Buffalo chemical engineers.

28 Oct 2008

Vitamin E and selenium do not prevent prostate cancer

A major study on whether vitamin E and selenium prevent prostate cancer has been stopped because the supplements are not effective and also because there is a suspicion of a risk.

28 Oct 2008

Expensive new diabetes drugs don't necessarily produce better outcomes

The annual cost of prescription diabetes drugs nearly doubled to $12.5 billion between 2001 and 2007, according to a study by researchers at the Stanford University School of Medicine and the University of Chicago. The researchers say the findings raise questions about whether the higher cost actually translates into improved care and better outcomes.

28 Oct 2008

Griffith University and Pfizer in new partnership to unlock nature's cure for infections

In the quest to develop the next generation of anti-infective medicine, Griffith University and Pfizer, the world's largest research-based pharmaceutical company, announced a leading partnership today.

27 Oct 2008

New strategy to treat human infections caused by the yeast Candida albicans

Researchers at Georgetown University Medical Center (GUMC) have successfully tested a genetic strategy designed to improve treatment of human infections caused by the yeast Candida albicans, ranging from diaper rash, vaginitis, oral infections (or thrush which is common in HIV/AIDS patients), as well as invasive, blood-borne and life-threatening diseases.

27 Oct 2008